- Home
- BLFY vs BDTX Comparison
BLFY vs BDTX Comparison
Compare BLFY & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFY
- BDTX
- Stock Information
- Founded
- BLFY 1939
- BDTX 2014
- Country
- BLFY United States
- BDTX United States
- Employees
- BLFY N/A
- BDTX N/A
- Industry
- BLFY Commercial Banks
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLFY Finance
- BDTX Health Care
- Exchange
- BLFY Nasdaq
- BDTX Nasdaq
- Market Cap
- BLFY 191.7M
- BDTX 181.4M
- IPO Year
- BLFY N/A
- BDTX 2020
- Fundamental
- Price
- BLFY $9.20
- BDTX $3.19
- Analyst Decision
- BLFY Hold
- BDTX Strong Buy
- Analyst Count
- BLFY 1
- BDTX 6
- Target Price
- BLFY $10.00
- BDTX $12.50
- AVG Volume (30 Days)
- BLFY 33.6K
- BDTX 805.6K
- Earning Date
- BLFY 10-22-2025
- BDTX 11-04-2025
- Dividend Yield
- BLFY N/A
- BDTX N/A
- EPS Growth
- BLFY N/A
- BDTX N/A
- EPS
- BLFY N/A
- BDTX 0.25
- Revenue
- BLFY $41,939,000.00
- BDTX $70,000,000.00
- Revenue This Year
- BLFY $20.35
- BDTX N/A
- Revenue Next Year
- BLFY $19.30
- BDTX N/A
- P/E Ratio
- BLFY N/A
- BDTX $12.74
- Revenue Growth
- BLFY 0.22
- BDTX N/A
- 52 Week Low
- BLFY $8.24
- BDTX $1.20
- 52 Week High
- BLFY $11.38
- BDTX $6.23
- Technical
- Relative Strength Index (RSI)
- BLFY 49.50
- BDTX 60.41
- Support Level
- BLFY $8.98
- BDTX $2.56
- Resistance Level
- BLFY $9.59
- BDTX $3.43
- Average True Range (ATR)
- BLFY 0.28
- BDTX 0.17
- MACD
- BLFY -0.02
- BDTX 0.04
- Stochastic Oscillator
- BLFY 33.85
- BDTX 67.57
About BLFY Blue Foundry Bancorp
Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.